

Thursday 10 October, 09:00 to 16:00
The Hibernia Conference Centre, Dublin Castle

Registration opens at 08:15

Tea/coffee and pastries on arrival

Opening

Stakeholder Perspectives on HTA

09.00 to 10.30

National HTA Agency

Prof Michael Barry, Clinical Director NCPE

Healthcare Decision Maker

Mr Niall Redmond, Department of Health

Industry

Mr Shane Ryan, IPHA President

Patient Organisation Liaison

Ms Joan O'Callaghan, NCPE

Public/Patient

Mr Fergal Griffin, Neurofibromatosis
Association of Ireland

Panel Discussion

Break

10.30 to 11.00

Plenary Session

11.00 to 12.10

Public policy issues around cancer medicines

Prof Richard Sullivan, Institute of Cancer
Policy, King's College London

Challenges with evidence for cancer medicines: A Belgian HTA
perspective

Dr Mattias Neyt, Belgian Healthcare
Knowledge Centre

Challenges with evidence for cancer medicines: NCPE research and
considerations

Dr Caroline Walsh, NCPE

Panel Discussion

National & International Perspectives on HTA

12.10 to 13.00

National HTA Update 2023-2024

Dr Lesley Tilson, NCPE

Challenges in HTA: An international HTA consultancy perspective

Dr Suzette Matthijsse, Lumanity

Q&A

Lunch

13.00 to 14.00

HTA in Practice

14.00 to 15.00

Developing an NCPE-adjusted Base Case

Dr Emer Fogarty, NCPE

International/National Horizon Scanning

Dr Roisin Adams, NCPE

Q&A

Implementation of the EU HTA Regulation

15.00 to 16.00

The Role of the NCPE Assessor in the JSC subgroup

Dr Niamh Carey, NCPE

Working Towards National Implementation of the EU HTA Regulation

Dr Emer Fogarty, NCPE

Panel Discussion

Closing Remarks

Prof Michael Barry